Dasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders

New scientific findings have recently shown that dasatinib (DAS), the first-choice oral drug in the treatment of chronic myeloid leukemia (CML) for adult patients who are resistant or intolerant to imatinib, is also potentially useful in the paediatric age. Moreover, recent preclinical evidences sug...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Mol Sci
Autori principali: Cutrignelli, Annalisa, Sanarica, Francesca, Lopalco, Antonio, Lopedota, Angela, Laquintana, Valentino, Franco, Massimo, Boccanegra, Brigida, Mantuano, Paola, De Luca, Annamaria, Denora, Nunzio
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6386909/
https://ncbi.nlm.nih.gov/pubmed/30704045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20030591
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi